President Donald Trump intends to nominate Heidi Overton, a White House official, to serve as the commissioner of the Food and Drug Administration (FDA). The decision was reported on Tuesday by sources familiar with the selection who spoke on the condition of anonymity. If confirmed, Overton would fill a vacancy that has been managed by acting leadership since May.
Overton currently serves as the deputy assistant to the president for domestic policy, a role focused on health policy that she began when the administration took office last year. Her professional background includes serving as the chief policy officer for the America First Policy Institute, a think tank aligned with Trump, where she directed the Center for a Healthy America. She also previously served as a fellow in the first Trump administration from 2019 to 2020 within the Office of American Innovation and the Domestic Policy Council.
The nominee is a medical doctor, board-certified in public health and general preventive medicine. She completed a general surgery residency at Johns Hopkins Hospital in Baltimore and holds a doctorate in clinical investigation from the same institution. During her time at Johns Hopkins, she co-authored a 2017 editorial with former FDA Commissioner Marty Makary regarding the role of surgical prescribing practices in the opioid crisis.
A confirmed commissioner provides permanent leadership to a workforce that has been under temporary direction for several months. For the average person, the change in leadership may eventually be noticed through shifts in federal health priorities or the implementation of new health policies developed at the White House. Because Overton has focused on health policy within the Domestic Policy Council, her transition to the FDA would place an official already involved in the administration's health agenda at the head of the primary regulatory body for medicine and food.
The nomination maintains a long-standing tradition of placing a medical professional at the head of the FDA, a precedent that has spanned several decades. The selection of a candidate with experience in both clinical medicine and domestic policy research indicates the administration's intended direction for the agency’s regulatory approach. What happens next is a formal nomination followed by a confirmation process in the U.S. Senate; however, specific dates for hearings or votes have not yet been announced. Until a permanent commissioner is confirmed, the agency will continue to operate under acting leadership.